FemasysFEMY +5.56%55 Days Payable is 983.66 as of Mar. 2026, which is 43% above its 10-year median of 686.60. GuruFocus rates FEMY with a GF Score™ of 55/100 and a GF Value™ of $12.22 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 796 Medical Devices & Instruments companies, Femasys ranks better than 95.48% on this metric.
Femasys's average Accounts Payable for the
three
months ended in Mar. 2026 was $1.71 Mil. Femasys's Cost of Goods Sold for the
three
months ended in Mar. 2026 was $0.16 Mil.
Hence, Femasys's Days Payable for the
three
months ended in Mar. 2026 was 983.66.
The historical rank and industry rank for Femasys's Days Payable or its related term are showing as below:
FEMY'
s Days Payable Range Over the Past 10 Years
Min: 395.14 Med: 686.6 Max: 895.35
Current: 895.35
During the past 7 years, Femasys's highest Days Payable was 895.35. The lowest was 395.14. And the median was 686.60.
FEMY's Days Payable is ranked better than 95.48% of 796
companies
in the Medical Devices & Instruments industry
Industry Median: 68.14
vs FEMY: 895.35
Femasys's Days Payable
declined
from Mar. 2025 (1,462.73) to Mar. 2026 (983.66).
It may suggest that Femasysaccelerated paying its suppliers.
Femasys Days Payable Related Terms
Femasys Days Payable Historical Data
* Premium members only.
The historical data trend for Femasys's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Femasys's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Femasys Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Femasys's Days Payable distribution charts can be found below:
* The bar in red indicates where Femasys's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Femasys's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Femasys (FEMY) has a Days Payable of 983.66 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Femasys and its competitors. This is 43% above median its historical median of 686.60. Over the past decade, Femasys' Days Payable has ranged from 395.14 to 895.35. According to the industry distribution chart, Femasys ranks #36 out of 796 companies in the Medical Devices & Instruments industry, placing it in the top 4.5%.
Is Femasys' Days Payable too high?
Femasys' current Days Payable of 983.66 is 43% above median its 10-year median of 686.60. Over the past 10 years, this metric has ranged from a low of 395.14 to a high of 895.35. The Medical Devices & Instruments industry median Days Payable is 68.14. Femasys' value of 983.66 is 1343.6% above this industry median. Based on the distribution chart, Femasys ranks #36 out of 796 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Femasys has a GF Score™ of 55/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Femasys' Days Payable compare to RVP and HBIO?
According to the Medical Devices & Instruments industry distribution chart, Femasys ranks #36 out of 796 companies for Days Payable. This places Femasys in the top 5% of its industry — outperforming the majority of peers. The industry median Days Payable is 68.14. Femasys' value of 983.66 is 1343.6% above this benchmark. Historically, Femasys' own Days Payable has ranged from 395.14 to 895.35 over the past decade. While the company's 10-year median is 686.60 vs. the industry median of 68.14, Femasys has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 68.14, based on 796 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Femasys's current Days Payable of 983.66 is 1343.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Femasys and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 68.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Femasys's current Days Payable is 983.66, which is 43% above median its own 10-year median of 686.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Femasys stock overvalued right now?
Based on GuruFocus' analysis, Femasys (FEMY) is currently considered Possible Value Trap. The stock's GF Value™ is $12.22, compared to a current price of $3.80 — trading 68.9% below its estimated fair value. The current Days Payable is 983.66, which is 43% above median its 10-year median of 686.60 and 1343.6% above the Medical Devices & Instruments industry median of 68.14. Femasys' overall GF Score™ is 55/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Femasys (FEMY), the current Days Payable is 983.66 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Femasys (FEMY) Overvalued in 2026?
Based on GuruFocus' analysis, Femasys stock appears to be undervalued.
The current stock price of $3.80 is trading 68.9% below its estimated GF Value™ of $12.22.
GuruFocus considers Femasys to be Possible Value Trap.
Key valuation signals for FEMY:
Days Payable: 983.66 (43% above median its 10-year median of 686.60)
GF Value™: $12.22 vs. price of $3.80 (68.9% below fair value)
Industry Position: 1343.6% above the Medical Devices & Instruments median (#36 of 796)
No single metric tells the full story. See the FEMY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.
55GF Score
Get the complete analysis for FEMY
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FEMY has been successfully added to your 
